Most of the Retatrutide conversation in Australia has been about one number: the 28.3% average body weight loss seen at 12mg in TRIUMPH-1. But the two trials Eli Lilly reported on 23 July 2026 — TRIUMPH-2 and TRIUMPH-3 — may matter more for retatrutide availability in Australia, because they shape who is likely to be able to access it first once the paperwork is done. In Australia, access to a new obesity medicine is rarely a single switch that flips on. It's a queue, and these two trials are effectively the drug's application to jump to the front of it for people with type 2 diabetes and established heart disease.

Here's what the new data says, and how the Australian access queue is likely to form.

What TRIUMPH-2 and TRIUMPH-3 actually found

TRIUMPH-2 studied adults with obesity or overweight plus type 2 diabetes. At 80 weeks, average weight loss was 12.7% at 4mg, 19.1% at 9mg and 20.8% at 12mg, alongside HbA1c reductions of up to 1.6 percentage points from a 7.7% baseline (placebo: 0.2). TRIUMPH-3 enrolled 1,949 adults with severe obesity and established cardiovascular disease, with or without type 2 diabetes, and reported 21.6%–22.6% mean weight loss on the 9mg and 12mg doses versus 3.2% on placebo, plus improvements in lipids, blood pressure, waist circumference and hsCRP.

Two honest caveats. First, weight loss was lower than TRIUMPH-1's headline 28.3% — that's the expected pattern for incretin drugs in people with type 2 diabetes, not a failure. Second, the cardiovascular event results in TRIUMPH-3 were not statistically significant (MACE-5 hazard ratio 0.82, 95% CI 0.55–1.22), reflecting low event numbers over 80 weeks. This trial was powered for weight, not for proving heart-attack prevention. Detailed TRIUMPH-2 and TRIUMPH-3 results have not yet been published in a peer-reviewed journal. You can track the full program on our clinical trials page.

Lilly also confirmed it plans to submit a Biologics License Application to the US FDA in the first quarter of 2027, telling media it needs more time to complete manufacturing and quality-control data.

Retatrutide availability in Australia: why "sickest first" is the likely pattern

Retatrutide is investigational and not TGA-approved. Nothing below changes that. But it's worth understanding how the sequence usually runs, because it explains why two people with the same BMI can end up with very different access.

Step 1: the TGA registration decision

The TGA can lean on assessments already completed by comparable overseas regulators. Its COR-B pathway carries a 175 working day evaluation and decision timeframe, and COR-A is shorter again at 120 working days for eligible applications. That's a meaningful shortcut — but the clock only starts once an Australian sponsor lodges, and lodgement here typically follows the US and EU filings rather than leading them. With a Q1 2027 FDA submission, a realistic Australian registration decision sits well beyond that. We break the timeline down further in our Australia access guide.

Step 2: the indication wording decides who's eligible

This is the part most people skip. Approval isn't generic — it comes with an approved indication. If retatrutide is registered for chronic weight management in adults with obesity, or overweight plus at least one weight-related comorbidity (the TRIUMPH-1 population), that's the on-label group. Data in people with type 2 diabetes and established CVD strengthens the case for those populations being explicitly named, which matters for prescriber confidence.

Step 3: subsidy — the real gate for most Australians

Registration means you can buy it. It doesn't mean it's affordable. Currently, GLP-1 medicines are not PBS-subsidised for obesity in Australia; PBS subsidy for semaglutide applies to eligible patients with type 2 diabetes, and the PBAC has publicly reviewed the question of equitable access to GLP-1 obesity treatments. If that pattern holds, the first Australians with subsidised access to a triple agonist are far more likely to be those with type 2 diabetes or serious metabolic complications than those seeking weight loss alone — which is precisely why TRIUMPH-2 and TRIUMPH-3 matter commercially, not just clinically.

What this means if you're waiting in Australia

With roughly 66.8% of Australian adults living with overweight or obesity, the eligible population is enormous — and that alone guarantees the initial access window will be rationed by indication, price and supply rather than by demand.

Practical things worth doing while you wait:

  • Get your baseline documented. Weight, waist circumference, HbA1c, lipids, blood pressure and any sleep apnoea or osteoarthritis diagnosis. Comorbidity documentation is what determines eligibility under restricted subsidy criteria.
  • Understand the class you can already discuss with a GP. Semaglutide (Ozempic/Wegovy) targets one receptor; tirzepatide (Mounjaro/Zepbound) targets two. Retatrutide adds glucagon as a third — see what is retatrutide for the mechanism.
  • Know the tolerability profile. Gastrointestinal side effects predominated in the new trials, with adverse-event discontinuations of 3.8%–11.6% on retatrutide versus 4.9% on placebo. More on our safety page.
  • Stay informed as filings happen. Join the free updates list and we'll email you when there's a real Australian milestone — a TGA lodgement, a PBAC agenda item, a publication.

FAQ

Is retatrutide available in Australia in 2026?

No. Retatrutide remains an investigational medicine that has not been approved by the TGA, and there is no registered product available through Australian pharmacies. Eli Lilly has said it plans to file with the US FDA in the first quarter of 2027, with other regulators to follow.

Who will be able to get retatrutide first in Australia?

Most likely people whose approved indication and subsidy criteria are met first — historically that has meant patients with type 2 diabetes or significant weight-related complications, rather than weight loss alone. The TRIUMPH-2 (type 2 diabetes) and TRIUMPH-3 (cardiovascular disease) results build the evidence base for exactly those groups.

How long does TGA approval take after an overseas approval?

The TGA's comparable overseas regulator pathways have published timeframes of 120 working days (COR-A) and 175 working days (COR-B) for evaluation and decision, but that clock only starts when an Australian sponsor lodges an application, which usually happens after the US and European filings.

Will retatrutide be on the PBS for weight loss?

It's unknown, and it would require a separate submission and a positive PBAC recommendation after TGA registration. At present GLP-1 medicines are not PBS-subsidised for obesity in Australia, so early access would likely be at full private cost.

Sources

Disclaimer: This article is general information only and is not medical advice. Retatrutide is investigational and is not approved by the TGA for use in Australia. Always speak with your GP or a qualified health professional about weight management and any medicine. retatrutide.net.au is an independent Australian information site and is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company.